By Sabela Ojea
Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.
The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.
The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.
The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.
"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris," Pieper said.
The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 06, 2025 12:10 ET (17:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.